Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 8

1.

Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumors.

Lorusso PM, Edelman MJ, Bever SL, Forman KM, Pilat M, Quinn MF, Li J, Heath EI, Malburg LM, Klein PJ, Leamon CP, Messmann RA, Sausville EA.

J Clin Oncol. 2012 Nov 10;30(32):4011-6. doi: 10.1200/JCO.2011.41.4946. Epub 2012 Oct 1.

2.

EC-145, a folate-targeted Vinca alkaloid conjugate for the potential treatment of folate receptor-expressing cancers.

Dosio F, Milla P, Cattel L.

Curr Opin Investig Drugs. 2010 Dec;11(12):1424-33. Review.

PMID:
21154124
3.

Vintafolide (EC145) for the treatment of folate-receptor-α positive platinum-resistant ovarian cancer.

Ambrosio AJ, Suzin D, Palmer EL, Penson RT.

Expert Rev Clin Pharmacol. 2014 Jul;7(4):443-50. doi: 10.1586/17512433.2014.909723. Epub 2014 Apr 18. Review.

PMID:
24742319
4.

The folate receptor as a rational therapeutic target for personalized cancer treatment.

Assaraf YG, Leamon CP, Reddy JA.

Drug Resist Updat. 2014 Oct-Dec;17(4-6):89-95. doi: 10.1016/j.drup.2014.10.002. Epub 2014 Oct 8. Review.

PMID:
25457975
5.

EC145: a novel targeted agent for adenocarcinoma of the lung.

Pribble P, Edelman MJ.

Expert Opin Investig Drugs. 2012 May;21(5):755-61. doi: 10.1517/13543784.2012.671294. Epub 2012 Mar 30. Review.

PMID:
22462761
6.

Profile of vintafolide (EC145) and its use in the treatment of platinum-resistant ovarian cancer.

Luyckx M, Votino R, Squifflet JL, Baurain JF.

Int J Womens Health. 2014 Mar 31;6:351-8. doi: 10.2147/IJWH.S39696. eCollection 2014. Review.

7.

Toxicity management in patients receiving low-dose aldesleukin therapy.

Sundin DJ, Wolin MJ.

Ann Pharmacother. 1998 Dec;32(12):1344-52. Review.

PMID:
9876817
8.

Vintafolide: a novel targeted therapy for the treatment of folate receptor expressing tumors.

Vergote I, Leamon CP.

Ther Adv Med Oncol. 2015 Jul;7(4):206-18. doi: 10.1177/1758834015584763. Review.

Supplemental Content

Support Center